• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氯贝丁酯与烟酸联合治疗对心肌再梗死的降低作用。

Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid.

作者信息

Carlson L A, Danielson M, Ekberg I, Klintemar B, Rosenhamer G

出版信息

Atherosclerosis. 1977 Sep;28(1):81-6. doi: 10.1016/0021-9150(77)90201-5.

DOI:10.1016/0021-9150(77)90201-5
PMID:911371
Abstract

In an ongoing study 558 consecutive survivors of myocardial infarction below 70 years, mean age 59 years, were randomly allocated 4 months after the acute episode into a control group or a chemotherapy group from December 1972 to April 1976. Both groups were given moderate advice about diet and the chemotherapy group was prescribed clofibrate, 1 g twice daily, and nicotinic acid 1 g three times daily. Serum cholesterol and triglycerides were lowered around 15-20% and 30% respectively in the chemotherapy group while only insignificant reductions were observed in the control group. Until December 1976 total mortality and mortality from IHD has been the same in the two groups. The number of non-fatal myocardial infarctions has been 38 in the control and 19 in the chemotherapy group, a statistically significant reduction (P less than 0.01).

摘要

在一项正在进行的研究中,558名年龄在70岁以下的心肌梗死连续幸存者,平均年龄59岁,于1972年12月至1976年4月急性发作4个月后被随机分为对照组或化疗组。两组均接受了适度的饮食建议,化疗组被开了氯贝丁酯,每日两次,每次1克,以及烟酸,每日三次,每次1克。化疗组的血清胆固醇和甘油三酯分别降低了约15 - 20%和30%,而对照组仅观察到微不足道的降低。直到1976年12月,两组的总死亡率和缺血性心脏病死亡率相同。对照组非致命性心肌梗死的数量为38例,化疗组为19例,有统计学意义的降低(P小于0.01)。

相似文献

1
Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid.氯贝丁酯与烟酸联合治疗对心肌再梗死的降低作用。
Atherosclerosis. 1977 Sep;28(1):81-6. doi: 10.1016/0021-9150(77)90201-5.
2
Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.
Acta Med Scand. 1988;223(5):405-18. doi: 10.1111/j.0954-6820.1988.tb15891.x.
3
Effect of combined clofibrate--nicotinic acid treatment in ischemic heart disease.氯贝丁酯与烟酸联合治疗对缺血性心脏病的影响。
Atherosclerosis. 1980 Sep;37(1):129-42. doi: 10.1016/0021-9150(80)90100-8.
4
[Value of lipid lowering drugs after myocardial infarction: results of the coronary drug project 1975 (author's transl)].心肌梗死后降脂药物的价值:1975年冠状动脉药物项目的结果(作者译)
Schweiz Rundsch Med Prax. 1975 Sep 16;64(37):1167-8.
5
Editorial: Lipid-lowering drugs after myocardial infarction.社论:心肌梗死后的降脂药物
Lancet. 1975 Mar 1;1(7905):501-2.
6
[Clofibrate therapy--the status quo].
Z Gesamte Inn Med. 1982 Jan 15;37(2):59-63.
7
Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians.缺血性心脏病:一项使用氯贝丁酯的二级预防试验。苏格兰医师协会研究委员会的报告。
Br Med J. 1971 Dec 25;4(5790):775-84.
8
The coronary drug project--findings with regard to estrogen, dextrothyroxine, clofibrate and niacin.冠状动脉药物项目——关于雌激素、右旋甲状腺素、氯贝丁酯和烟酸的研究结果。
Adv Exp Med Biol. 1977;82:52-75. doi: 10.1007/978-1-4613-4220-5_6.
9
Coronary Drug Project report on clofibrate and niacin.冠心病药物研究项目关于氯贝丁酯和烟酸的报告。
Atherosclerosis. 1978 Jul;30(3):239-40.
10
Dose-response effect of single and combined clofibrate (Atromidin) and niceritrol (Perycit) treatment on serum lipids and lipoproteins in type II hyperlipoproteinaemia.
Atherosclerosis. 1975 Jul-Aug;22(1):91-101. doi: 10.1016/0021-9150(75)90070-2.

引用本文的文献

1
Dyslipidemia: A Narrative Review on Pharmacotherapy.血脂异常:药物治疗的叙述性综述
Pharmaceuticals (Basel). 2024 Feb 23;17(3):289. doi: 10.3390/ph17030289.
2
Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases.高α脂蛋白血症及其他:高密度脂蛋白在心血管疾病中的作用
Life (Basel). 2021 Jun 18;11(6):581. doi: 10.3390/life11060581.
3
Drug Therapy of Dyslipidemia in the Elderly.老年人血脂异常的药物治疗
Drugs Aging. 2019 Apr;36(4):321-340. doi: 10.1007/s40266-018-00632-x.
4
All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.所有降胆固醇干预措施预计均可降低中风风险:来自IMPROVE-IT的确证数据。
Data Brief. 2016 Apr 27;7:1541-50. doi: 10.1016/j.dib.2016.04.059. eCollection 2016 Jun.
5
Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?从新的临床试验看烟酸在高脂血症治疗中的应用:烟酸是否已失去其地位?
Med Sci Monit. 2015 Jul 25;21:2156-62. doi: 10.12659/MSM.893619.
6
Recognition and management of hypercholesterolaemia in patients awaiting elective coronary artery bypass grafting.择期冠状动脉旁路移植术患者高胆固醇血症的识别与管理
Postgrad Med J. 1998 Mar;74(869):157-60. doi: 10.1136/pgmj.74.869.157.
7
Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta-analysis.随机试验中冠心病发病率和总死亡率与血浆胆固醇降低的关系:荟萃分析的应用
Br Heart J. 1993 Jan;69(1 Suppl):S42-7. doi: 10.1136/hrt.69.1_suppl.s42.
8
Peculiarities of hyperlipidaemia in tumour patients.肿瘤患者高脂血症的特点
Br J Cancer. 1981 May;43(5):637-43. doi: 10.1038/bjc.1981.94.
9
Dietary prevention of ischaemic heart disease--a policy for the '80s.缺血性心脏病的饮食预防——八十年代的一项政策。
Br Med J. 1980 Jul 19;281(6234):177-80. doi: 10.1136/bmj.281.6234.177.
10
Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects.在接受慢性血液透析的患者中使用苯扎贝特进行降脂治疗:药代动力学及疗效
Klin Wochenschr. 1986 Oct 1;64(19):910-6. doi: 10.1007/BF01728614.